Sofya Prakhova

Dr. Sofya Prakhova

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Applied Mathematical Sciences
Verified
Journal Article
Open access
SPSofya Prakhova
Sofya Prakhova
ISIgor Suleimanov
Igor Suleimanov
VRVolker Rehbock
Volker Rehbock

15 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SPSofya Prakhova
Sofya Prakhova
We evaluated performance of two American surveillance systems for monitoring the spread of antimicrobial-resistant (AMR) gonorrhea: the Gonococcal Isolate Surveillance Project (GISP) and the enhanced Gonococcal Isolate Surveillance Project (eGISP) which includes the non-urethral isolates in addition to the urethral ones utilized in the original surveillance system. A continuous-time agent-based model of gonorrhea transmission among the US men who have sex with men (MSM) population was developed and used for this purpose. The accuracy of eGISP was nearly 10% higher than the accuracy of GISP (97.8% (95% uncertainty interval: 83.5%, 100%) vs. 87.9% (55%, 100%)). Most of time, GISP detects the moment when the resistance to the current first-line antibiotic reaches the switch threshold recommended by the WHO later than when it was actually reached. This leads to the additional spread of AMR gonorrhea. Informing the treatment guidelines for gonorrhea by eGISP estimates would avert more gonorrhea cases than basing them on the currently used GISP estimates (11.8M (0.5M, 38.5M) vs. 11.3M (0.4M, 42M) gonorrhea cases over 25 years). Finally, we demonstrate that including the extragenital isolates in the surveillance is more important for the accurate monitoring of the spread than increasing the size of the resistant-based surveys. These findings provide a scientific basis which can be used by the policymakers who decide how many GISP and eGISP sites to establish each year.

19 March 2020 in arXiv
Verified
Preprint
Open access
PDF file
SPSofya Prakhova
Sofya Prakhova
VRVolker Rehbock
Volker Rehbock
ISIgor Suleimanov
Igor Suleimanov
In this paper, we incorporate seasonal variations of insolation into the global climate model C-GOLDSTEIN. We use a new approach for modelling insolation from the space perspective presented in the authors' earlier work and build it into the existing climate model. Realistic monthly temperature distributions have been obtained after running C-GOLDSTEIN with the new insolation component. Also, the average accuracy of modelling the insolation within the model has been increased by 2%. In addition, new types of experiments can now be performed with C-GOLDSTEIN, such as the investigation of consequences of random variations of insolation on temperature etc.

29 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SPSofya Prakhova
Sofya Prakhova
Background The Gonococcal Isolate Surveillance Project (GISP) is a sentinel surveillance system to monitor the spread of antimicrobial-resistant (AMR) gonorrhea. Under GISP surveillance strategy, urethral isolates are utilized for monitoring the spread and the obtained estimates are used for informing the gonorrhea treatment guidelines. In 2017, the enhanced Gonococcal Isolate Surveillance Project (eGISP) was established which also includes the non-urethral isolates. Using eGISP estimates for informing the gonorrhea treatment guidelines is an alternative surveillance strategy that can be used. We aim to investigate cost-effectiveness of both strategies. Methods We utilized our previously developed continuous-time agent-based model of gonorrhea transmission among the US men who have sex with men (MSM) population and calculated the total number of discounted quality-adjusted life years (QALYs) and total discounted costs over 35 years under GISP and eGISP surveillance strategy. We also evaluated cost-effectiveness of both surveillance strategies. Results Under GISP surveillance strategy, $10.7M (95% uncertainty interval: $1.4M, $27.3M) were saved and 119.9 (12.9, 354.4) QALYs were gained over 35 years compared to no surveillance in the simulated cohort of 10,000 US MSM. Performing eGISP surveillance strategy instead would result in additional $29,282 (-$566,895, $700,595) saved and 0.25 (-6.7, 7.6) QALYs gained. Conclusion The current GISP surveillance strategy significantly reduces the costs and increases the health benefits compared to no surveillance. However, switching from the current strategy to eGISP strategy is cost saving and should be considered in order to improve the population health and reduce the financial burden of gonorrhea.

24 February 2026 in Venereology
Verified
Journal Article
Open access
PDF file
SPSofya Prakhova
Sofya Prakhova
Background: The surveillance of antimicrobial-resistant (AMR) gonorrhea in the United States is conducted under the Gonococcal Isolate Surveillance Project (GISP). Its protocol involves the collection of urethral isolates from the symptomatic men diagnosed with urethral gonorrhea at designated surveillance sites and the estimation of the percentage of cases resistant to current and former gonorrhea antibiotics. A switch to a new antibiotic is typically made when this percentage for a current first-line drug reaches 5%. However, the cost-effectiveness of this surveillance strategy has never been assessed. Methods: We utilized our previously developed agent-based model of gonorrhea transmission among the US men who have sex with men (MSM) population and estimated the total number of gonorrhea cases, total number of discounted quality-adjusted life years (QALYs) and total discounted costs over 25 years under the current surveillance strategy and under a scenario with no surveillance. Results: The maintenance of the current surveillance strategy is projected to avert 104,108 (95% uncertainty interval: 9163, 213,238) gonorrhea cases, gain 192.9 (95% uncertainty interval: 6, 458.3) QALYs and save $38.6 million (95% uncertainty interval: $1 million, $68.2 million) in the simulated cohort of 10,000 US MSM over a 25-year period (2023–2048) when compared to a scenario with no surveillance. Conclusions: The current US surveillance strategy for AMR gonorrhea is cost-saving. However, the low-bound estimate indicates limited savings of $1 million, which is relatively modest at a national scale.